Madrid, Spain and Heidelberg, Germany, October 1, 2015 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it will present its proprietary portfolio of TruePrime(TM) and SunScript(TM) technologies for DNA amplification and sequencing at the Annual Meeting of the American Society of Human Genetics (ASHG), the ASHG 2015, which will be held from October 6 - 10, 2015 in Baltimore, Maryland. The ASHG today is the largest human genetics meeting worldwide with more than 6,500 attendees and over 200 exhibiting companies and represents a forum for presentations and discussions of cutting-edge science in all areas of human genetics.
Miguel Viribay Vice President Marketing and Sales at SYGNIS and Ángel J. Picher, Associate Director, Product Development will promote both the TruePrime(TM) and SunScript(TM) product lines at the Company's own booth (number 2019). In addition, they will highlight and discuss the latest results of deep sequencing obtained with the TruePrime(TM) technology, that show superior genome coverage even from single cells when compared to traditional competing technologies, with key opinion leaders and potential future partners from the human genomics field.
'After rolling out our proprietary portfolio of products for DNA amplification and sequencing in Europe and building a strong network of distributors to cover the European markets, we are now moving forward in our product and commercialization strategy to more actively promote our products in the U.S., the main market for our innovative technologies,' commented Pilar de la Huerta, CEO and CFO of SYGNIS AG . 'Presenting and hosting an own booth on a conference like the ASHG 2015, the most renowned event in the field of human genetics, is a huge opportunity for us to increase and improve the visibility of our products and technologies in U.S. markets.'
For more information on the ASHG 2015 Annual Meeting, please visit: http://www.ashg.org/2015meeting/.
About TruePrime(TM)
TruePrime(TM) is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS' portfolio. Based on the Company's proprietary TruePrime(TM) technology, TruePrime(TM) products allow the amplification of various DNA or RNA species from smallest amounts of biological samples down to single cells without the need of any synthetic random primers (oligonucleotides) for use with a multitude of applications including next generation sequencing and single cell analysis. TruePrime(TM) products provide superior advantages including the complete absence of common artifacts linked to the use of oligonucleotides, the reduced amplification bias in genome coverage, outstanding reliability as the technology is insensitive to external DNA contaminations, a high reproducibility, plus a superior sensitivity and ease of use.
About SunScript(TM) RT
SYGNIS' SunScript(TM) product line covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as next generation sequencing or polymerase chain reaction (PCR) for a broad range of applications in gene expression profiling and molecular diagnostics.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
Miguel Viribay Vice President Marketing and Sales at SYGNIS and Ángel J. Picher, Associate Director, Product Development will promote both the TruePrime(TM) and SunScript(TM) product lines at the Company's own booth (number 2019). In addition, they will highlight and discuss the latest results of deep sequencing obtained with the TruePrime(TM) technology, that show superior genome coverage even from single cells when compared to traditional competing technologies, with key opinion leaders and potential future partners from the human genomics field.
'After rolling out our proprietary portfolio of products for DNA amplification and sequencing in Europe and building a strong network of distributors to cover the European markets, we are now moving forward in our product and commercialization strategy to more actively promote our products in the U.S., the main market for our innovative technologies,' commented Pilar de la Huerta, CEO and CFO of SYGNIS AG . 'Presenting and hosting an own booth on a conference like the ASHG 2015, the most renowned event in the field of human genetics, is a huge opportunity for us to increase and improve the visibility of our products and technologies in U.S. markets.'
For more information on the ASHG 2015 Annual Meeting, please visit: http://www.ashg.org/2015meeting/.
About TruePrime(TM)
TruePrime(TM) is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS' portfolio. Based on the Company's proprietary TruePrime(TM) technology, TruePrime(TM) products allow the amplification of various DNA or RNA species from smallest amounts of biological samples down to single cells without the need of any synthetic random primers (oligonucleotides) for use with a multitude of applications including next generation sequencing and single cell analysis. TruePrime(TM) products provide superior advantages including the complete absence of common artifacts linked to the use of oligonucleotides, the reduced amplification bias in genome coverage, outstanding reliability as the technology is insensitive to external DNA contaminations, a high reproducibility, plus a superior sensitivity and ease of use.
About SunScript(TM) RT
SYGNIS' SunScript(TM) product line covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as next generation sequencing or polymerase chain reaction (PCR) for a broad range of applications in gene expression profiling and molecular diagnostics.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
